Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

S. Daayana, E. Elkord, U. Winters, M. Pawlita, R. Roden, P. L. Stern, H. C. Kitchener

Research output: Contribution to journalArticle

Abstract

Background:Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure.Methods:We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed.Results:Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10, increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens.Conclusion:The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.

Original languageEnglish (US)
Pages (from-to)1129-1136
Number of pages8
JournalBritish journal of cancer
Volume102
Issue number7
DOIs
StatePublished - Mar 1 2010

Keywords

  • Imiquimod
  • T regulatory cells
  • Therapeutic HPV vaccination
  • Vulval intraepithelial neoplasia (VIN)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia'. Together they form a unique fingerprint.

  • Cite this